

16 Apr 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: partial US clinical hold for evobrutinib; Takeda pulls back early AAV gene therapy and rare hematology research; Lilly and Novo shape up for obesity battle; Vir's new CEO talks to *Scrip*; and the declining state of pain R&D.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 14 April 2023, including: partial US clinical hold for evobrutinib; [*Takeda Pharmaceutical Co. Ltd.*](#) pulls back early AAV gene therapy and rare hematology research; [*Eli Lilly and Company*](#) and [*Novo Nordisk A/S*](#) shape up for obesity battle; [*Vir Biotechnology, Inc.*](#)'s new CEO talks to *Scrip*; and the declining state of pain R&D.

This and all our other podcasts are available on the Pharma Intelligence channel on [*Apple Podcasts*](#), [*Google Podcasts*](#), [*SoundCloud*](#), [*TuneIn*](#) and [*Spotify Podcasts*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[*Clinical Hold For Merck KGaA's BTK Inhibitor Evobrutinib For MS Raises Class Safety Fears*](#)" - *Scrip*, 12 Apr, 2023.)

(Also see "[*Takeda Halts Early R&D Efforts In AAV Gene Therapies And Rare Hematology*](#)" - *Scrip*, 12 Apr, 2023.)

(Also see "[*Lilly And Novo Nordisk Shape Up For Obesity Treatment Battle Of The Heavyweights*](#)" - *Scrip*, 6 Apr, 2023.)

(Also see "[*Big Year Ahead For New Vir CEO De Backer*](#)" - *Scrip*, 11 Apr, 2023.)

(Also see "[Pain Therapy R&D Innovation, Investment Declining, BIO Reports](#)" - Scrip, 7 Apr, 2023.)

[Click here to explore this interactive content online](#) ✨